These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 5481776)

  • 81. Clinical pharmacology as an approach to the study of biochemical sleep mechanisms: the action of L-dopa.
    Bergonzi P; Chiurulla C; Cianchetti C; Tempesta E
    Confin Neurol; 1974; 36(1):5-22. PubMed ID: 4363375
    [No Abstract]   [Full Text] [Related]  

  • 82. Letter: Levodopa and L-arginine to test GH release in obesity.
    D'Allessandro B; Bellastella A; Esposito V; Gasbarro R
    N Engl J Med; 1974 Mar; 290(10):575. PubMed ID: 4811111
    [No Abstract]   [Full Text] [Related]  

  • 83. [Improvement of growth-hormone stimulation with l-dopa/l-carbidopa by simultaneous administration of propranolol (author's transl)].
    Schönberger W; Grimm W; Ziegler R
    Dtsch Med Wochenschr; 1979 Dec; 104(51):1811-3. PubMed ID: 520175
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Effect of L-dopa and propranolol administration on GH secretion in essential obesity in women].
    Cabezas-Cerrato J; Mur AL; Aranguren LV; Vila T; Fernández-Cruz A
    Rev Clin Esp; 1975 Jun; 137(6):497-502. PubMed ID: 1162133
    [No Abstract]   [Full Text] [Related]  

  • 85. Prevention of L-dopa-induced growth hormone stimulation by hyperglycemia.
    Mims RB; Scott CL; Modebe OM; Bethune JE
    J Clin Endocrinol Metab; 1973 Nov; 37(5):660-3. PubMed ID: 4749441
    [No Abstract]   [Full Text] [Related]  

  • 86. Serotonin content of platelet enriched plasma in Parkinson patients prior and during treatment with L-3,4-dihydroxyphenylalanine (L-DOPA).
    Yamaguchi K; Tomasi L; Cote LJ; Barrett R; Yahr MD
    Biochem Med; 1972 Jun; 6(3):210-5. PubMed ID: 5041890
    [No Abstract]   [Full Text] [Related]  

  • 87. Similarities between neurologic effects of L-dopa and of apomorphine.
    Cotzias GC; Papavasiliou PS; Fehling C; Kaufman B; Mena I
    N Engl J Med; 1970 Jan; 282(1):31-3. PubMed ID: 4901383
    [No Abstract]   [Full Text] [Related]  

  • 88. Electrocardiographic and behavioral effects of L-DOPA in the guinea pig.
    Marino A; Girone E; Battista O; De Marino V
    Experientia; 1970 Sep; 26(9):983-4. PubMed ID: 5478646
    [No Abstract]   [Full Text] [Related]  

  • 89. Changes of serum growth hormone in psychosomatic disorders.
    Suematsu H; Kurokawa N; Tamai H; Ikemi Y
    Psychother Psychosom; 1974; 24(2):161-4. PubMed ID: 4850971
    [No Abstract]   [Full Text] [Related]  

  • 90. Involvement of 5-hydroxytryptamine in the cortical synchronization induced by L-DOPA in the rabbit.
    Gaillard JM; Bartholini G; Herkert B; Tissot R
    Brain Res; 1974 Mar; 68(2):344-50. PubMed ID: 4275029
    [No Abstract]   [Full Text] [Related]  

  • 91. Effects of L-DOPA treatment on indole metabolism in Parkinson's disease.
    Brune GG; Pflughaupt KW
    Experientia; 1971 May; 27(5):516. PubMed ID: 5132580
    [No Abstract]   [Full Text] [Related]  

  • 92. Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances.
    Lehmann J
    Acta Med Scand; 1973; 194(3):181-9. PubMed ID: 4746526
    [No Abstract]   [Full Text] [Related]  

  • 93. Growth hormone and prolactin in unipolar and bipolar depressed patients: responses to hypoglycemia and L-dopa.
    Sachar EJ; Frantz AG; Altman N; Sassin J
    Am J Psychiatry; 1973 Dec; 130(12):1362-7. PubMed ID: 4356808
    [No Abstract]   [Full Text] [Related]  

  • 94. Growth hormone. Control of release and characteristics in plasma.
    Beck JC; Bala MR; Ferguson KA; Kudo CF; Rubinstein D
    Trans Am Clin Climatol Assoc; 1972; 83():18-44. PubMed ID: 4625131
    [No Abstract]   [Full Text] [Related]  

  • 95. A survey of growth hormone secretion and action.
    Merimee TJ; Rabin D
    Metabolism; 1973 Sep; 22(9):1235-51. PubMed ID: 4580079
    [No Abstract]   [Full Text] [Related]  

  • 96. A preliminary study of selected emotional changes in Parkinsonians on L-dopa therapy.
    Maskin MB; Riklan M; Chabot D
    J Clin Psychol; 1972 Oct; 28(4):604-5. PubMed ID: 5080854
    [No Abstract]   [Full Text] [Related]  

  • 97. Intestinal decarboxylation of L-Dopa in relation to dose requirement in Parkinson's disease.
    Granerus AK; Jagenburg R; Svanborg A
    Naunyn Schmiedebergs Arch Pharmacol; 1973; 280(4):429-39. PubMed ID: 4274706
    [No Abstract]   [Full Text] [Related]  

  • 98. Effect of amantadine on L-2-14C-dopa metabolism in parkinsonism.
    Peaston MJ; Bianchine JR; Messiha FS
    Life Sci; 1973 Aug; 13(3):237-46. PubMed ID: 4750920
    [No Abstract]   [Full Text] [Related]  

  • 99. The activating effect of L-dopa treatment on sexual functions and its experimental background.
    Hyyppä M; Rinne UK; Sonninen V
    Acta Neurol Scand; 1970; 46(S43):223-4. PubMed ID: 5466273
    [No Abstract]   [Full Text] [Related]  

  • 100. Effect of synthetic somatotropin release inhibiting factor on the increase in plasma growth hormone elicited by L-dopa in the dog.
    Lovinger R; Boryczka AT; Shackelford R; Kaplan SL; Ganong WF; Grumbach MM
    Endocrinology; 1974 Oct; 95(4):943-6. PubMed ID: 4606498
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.